Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorBeijing Hospital
About this trial
The efficacy, safety and post-treatment disease control will be compared between groups of continuous subcutaneous Beinaglutide infusion and continuous subcutaneous insulin infusion (CSII) in adult patients with newly diagnosed type 2 diabetes.
Eligibility criteria
Qualifiers
Age 18 to 70 years (inclusive) at enrollment, regardless of gender.
Voluntary signing of the informed consent form.
Newly diagnosed type 2 diabetes mellitus patients, diagnosed according to the WHO 1999 criteria, with a disease duration ≤1 year.
HbA1c between 7.5% and 10.0%.
Disqualifiers
Patients with type 1 diabetes or other types of diabetes.
History of obstructive intestinal diseases or potential complications: subjects with post-abdominal surgery or peritoneal infection-related intestinal adhesions, intestinal obstruction sequelae; subjects with intestinal motility disorders, chronic constipation; subjects with a history of Crohn's disease or ulcerative colitis.
History of pancreatitis.
Family history of medullary thyroid carcinoma.
Trial design
Treatments tested in this trial
- Beinaglutide
- Insulin aspart
Treatment groups
115 Participants
are divided into 2 treatment groupsLocations
16Capital Medical University Beijing Anzhen Hospital BeijingBeijing Municipality, China
Emergency General Hospital BeijingBeijing Municipality, China
Peking University Shougang Hospital BeijingBeijing Municipality, China
Pinggu District Hospital000, BeijingBeijing Municipality, China
Sponsors and collaborators
Beijing Hospital
Lead sponsor
Source ClinicalTrials.gov